AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6

Molecular Therapy Methods and Clinical Development

Volumn 10, Issue , 2018, Pages 291-302

  Denard, Jérôme ^a   Rouillon, Jérémy ^a   Leger, Thibaut ^b   Garcia, Camille ^b   Lambert, Michele P ^c   Griffith, Graziella ^d   Jenny, Christine ^a   Camadro, Jean Michel ^b   Garcia, Luis ^d   Svinartchouk, Fedor ^a,d  

^a GÉNÉTHON   (France)

^b INSTITUT JACQUES MONOD   (France)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

adeno associated vectors; blood proteins; platelet factor 4; virus host interactions

Indexed keywords

APOLIPOPROTEIN E; BILE ACID; BINDING PROTEIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE 1; CLUSTERIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FARNESOID X RECEPTOR; FIBRONECTIN; GALECTIN 3; GLUTATHIONE PEROXIDASE 3; HUMAN SERUM ALBUMIN; HYALURONIC ACID BINDING PROTEIN; INTER ALPHA TRYPSIN INHIBITOR; LIPID; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPROTEIN; LIVER X RECEPTOR; METALLOPROTEINASE INHIBITOR; PLASMA PROTEIN; PLASMINOGEN; PROTEASE NEXIN I; PROTHROMBIN; RETINOID X RECEPTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; VIRUS VECTOR; VITRONECTIN;

ADENO ASSOCIATED VIRUS 6; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IN VIVO STUDY; MOUSE; NEUROMUSCULAR DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; QUALITATIVE ANALYSIS; SKELETAL MUSCLE;

EID: 85052150665     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1016/j.omtm.2018.08.001     Document Type: Article

References (46)

1. Summerford, C., Samulski, R.J., Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72 (1998), 1438–1445.
2. O'Donnell, J., Taylor, K.A., Chapman, M.S., Adeno-associated virus-2 and its primary cellular receptor—cryo-EM structure of a heparin complex. Virology 385 (2009), 434–443.
3. Wu, Z., Miller, E., Agbandje-McKenna, M., Samulski, R.J., Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80 (2006), 9093–9103.
4. Cheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L.G., Gee, S.W., McGoogan, K.E., Aslanidi, G.V., Park, M., Stacpoole, P.W., et al. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther. 19 (2012), 375–384.
5. Ling, C., Lu, Y., Kalsi, J.K., Jayandharan, G.R., Li, B., Ma, W., Cheng, B., Gee, S.W., McGoogan, K.E., Govindasamy, L., et al. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum. Gene Ther. 21 (2010), 1741–1747.
6. Bartlett, J.S., Wilcher, R., Samulski, R.J., Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74 (2000), 2777–2785.
7. Seiler, M.P., Miller, A.D., Zabner, J., Halbert, C.L., Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum. Gene Ther. 17 (2006), 10–19.
8. Schuhmann, N.K., Pozzoli, O., Sallach, J., Huber, A., Avitabile, D., Perabo, L., Rappl, G., Capogrossi, M.C., Hallek, M., Pesce, M., Büning, H., Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors. Exp. Hematol. 38 (2010), 707–717.
9. Denard, J., Beley, C., Kotin, R., Lai-Kuen, R., Blot, S., Leh, H., Asokan, A., Samulski, R.J., Moullier, P., Voit, T., et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol. 86 (2012), 6620–6631.
10. Denard, J., Marolleau, B., Jenny, C., Rao, T.N., Fehling, H.J., Voit, T., Svinartchouk, F., C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J. Virol. 87 (2013), 10784–10791.
11. Zhang, R., Barton, A., Brittenden, J., Huang, J.T.-J., Crowther, D., Evaluation for computational platforms of LC-MS based label-free quantitative proteomics: a global view. J. Proteomics Bioinform. 3 (2010), 260–265.
12. Wang, M., Sun, J., Crosby, A., Woodard, K., Hirsch, M.L., Samulski, R.J., Li, C., Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications. Gene Ther. 24 (2017), 49–59.
13. Mullick, J., Kadam, A., Sahu, A., Herpes and pox viral complement control proteins: ‘the mask of self’. Trends Immunol. 24 (2003), 500–507.
14. Blue, C.E., Spiller, O.B., Blackbourn, D.J., The relevance of complement to virus biology. Virology 319 (2004), 176–184.
15. Lambert, M.P., Rauova, L., Bailey, M., Sola-Visner, M.C., Kowalska, M.A., Poncz, M., Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood 110 (2007), 1153–1160.
16. Kowalska, M.A., Mahmud, S.A., Lambert, M.P., Poncz, M., Slungaard, A., Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood 110 (2007), 1903–1905.
17. Lambert, M.P., Wang, Y., Bdeir, K.H., Nguyen, Y., Kowalska, M.A., Poncz, M., Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood 114 (2009), 2290–2298.
18. Wang, D., Zhong, L., Nahid, M.A., Gao, G., The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin. Drug Deliv. 11 (2014), 345–364.
19. Kowalska, M.A., Rauova, L., Poncz, M., Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb. Res. 125 (2010), 292–296.
20. Windelov, N.A., Ostrowski, S.R., Johansson, P.I., Wanscher, M., Larsen, C.F., Sorensen, A.M., et al. Circulating levels of platelet α-granule cytokines in trauma patients. Inflamm Res. 64 (2015), 235–241.
21. Zucker, M.B., Katz, I.R., Platelet factor 4: production, structure, and physiologic and immunologic action. Proc. Soc. Exp. Biol. Med. 198 (1991), 693–702.
22. Zincarelli, C., Soltys, S., Rengo, G., Rabinowitz, J.E., Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16 (2008), 1073–1080.
23. Akache, B., Grimm, D., Pandey, K., Yant, S.R., Xu, H., Kay, M.A., The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80 (2006), 9831–9836.
24. Hauck, B., Xiao, W., Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 77 (2003), 2768–2774.
25. Kaludov, N., Brown, K.E., Walters, R.W., Zabner, J., Chiorini, J.A., Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75 (2001), 6884–6893.
26. Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., Daida, H., Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79 (2005), 609–614.
27. Shen, S., Bryant, K.D., Brown, S.M., Randell, S.H., Asokan, A., Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286 (2011), 13532–13540.
28. Shen, S., Bryant, K.D., Sun, J., Brown, S.M., Troupes, A., Pulicherla, N., Asokan, A., Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J. Virol. 86 (2012), 10408–10417.
29. Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A.C., Plovie, E., et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 12 (2015), 1056–1068.
30. Ng, R., Govindasamy, L., Gurda, B.L., McKenna, R., Kozyreva, O.G., Samulski, R.J., Parent, K.N., Baker, T.S., Agbandje-McKenna, M., Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84 (2010), 12945–12957.
31. Nonnenmacher, M., Weber, T., Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther. 19 (2012), 649–658.
32. Pillay, S., Meyer, N.L., Puschnik, A.S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L.T., Wosen, J.E., Nagamine, C.M., Chapman, M.S., Carette, J.E., An essential receptor for adeno-associated virus infection. Nature 530 (2016), 108–112.
33. Pillay, S., Zou, W., Cheng, F., Puschnik, A.S., Meyer, N.L., Ganaie, S.S., Deng, X., Wosen, J.E., Davulcu, O., Yan, Z., et al. AAV serotypes have distinctive interactions with domains of the cellular receptor AAVR. J. Virol., 91, 2017 e00391-17.
34. Stoermer, K.A., Morrison, T.E., Complement and viral pathogenesis. Virology 411 (2011), 362–373.
35. Fingeroth, J.D., Weis, J.J., Tedder, T.F., Strominger, J.L., Biro, P.A., Fearon, D.T., Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 81 (1984), 4510–4514.
36. Tugizov, S.M., Berline, J.W., Palefsky, J.M., Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat. Med. 9 (2003), 307–314.
37. Gaggar, A., Shayakhmetov, D.M., Lieber, A., CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9 (2003), 1408–1412.
38. Segerman, A., Atkinson, J.P., Marttila, M., Dennerquist, V., Wadell, G., Arnberg, N., Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77 (2003), 9183–9191.
39. Galkina, E., Ley, K., Immune and inflammatory mechanisms of atherosclerosis (*). Annu. Rev. Immunol. 27 (2009), 165–197.
40. Yeaman, M.R., Yount, N.Y., Waring, A.J., Gank, K.D., Kupferwasser, D., Wiese, R., Bayer, A.S., Welch, W.H., Modular determinants of antimicrobial activity in platelet factor-4 family kinocidins. Biochim. Biophys. Acta 1768 (2007), 609–619.
41. Sachais, B.S., Higazi, A.A., Cines, D.B., Poncz, M., Kowalska, M.A., Interactions of platelet factor 4 with the vessel wall. Semin. Thromb. Hemost. 30 (2004), 351–358.
42. Drittanti, L., Jenny, C., Poulard, K., Samba, A., Manceau, P., Soria, N., Vincent, N., Danos, O., Vega, M., Optimised helper virus-free production of high-quality adeno-associated virus vectors. J. Gene Med. 3 (2001), 59–71.
43. Wright, J.F., Transient transfection methods for clinical adeno-associated viral vector production. Hum. Gene Ther. 20 (2009), 698–706.
44. Smith, R.H., Levy, J.R., Kotin, R.M., A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther. 17 (2009), 1888–1896.
45. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F., Masurier, C., Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21 (2010), 704–712.
46. Rouillon, J., Poupiot, J., Zocevic, A., Amor, F., Léger, T., Garcia, C., Camadro, J.M., Wong, B., Pinilla, R., Cosette, J., et al. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Hum. Mol. Genet. 24 (2015), 4916–4932.